Insulin biosimilars have emerged as a crucial development in diabetes management, offering cost-effective alternatives to branded insulin products. These biosimilars are biologic medicines highly similar to already approved insulin therapies, providing comparable safety, efficacy, and quality. The escalating prevalence of diabetes worldwide and the increasing burden of healthcare cost... https://www.coherentmarketinsights.com/market-insight/insulin-biosimilars-market-1750